Brickell Biotech (BBI) Prices 17.5M Share Common Offering at 1.15/Sh

Brickell Biotech, Inc. (“Brickell”) (NASDAQ: BBI) today announced the pricing of an underwritten public offering of 17,500,000 shares of common stock or common stock equivalents (which includes pre-funded warrants to purchase shares of common stock in lieu of shares of common stock) and investor warrants to purchase up to an aggregate of 17,500,000 shares of common stock. Each share of common stock (or pre-funded warrant in lieu thereof) is being sold together with one investor warrant to purchase one share of common stock at a combined offering price of $1.15, for total gross proceeds of approximately $20.1 million, before underwriting discounts and commissions and offering expenses payable by Brickell. The offering is expected to close on or about June 22, 2020, subject to the satisfaction or waiver of customary closing conditions.

Brickell anticipates using the net proceeds from the offering for research and development, including clinical trials, working capital and general corporate purposes.

Oppenheimer & Co. Inc. is acting as the sole book-running manager in connection with the offering and Lake Street Capital Markets, LLC is acting as lead manager.

You May Also Be Interested In

• ZeroStack to receive $1B in Memecore tokens in equity deal
• Intellicheck lands wealth management client via channel partner
• SKK Holdings wins six Singapore drilling contracts worth $26.6M